Venus Remedies’ Vancoplus gets patent from Australia

10 Apr 2012 Evaluate

Venus Remedies has added one more patent to its kitty for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. After Potentox, this is the company’s second patent grant from the Australian Patent office (APO), Government of Australia, and is valid till February 2026.

The total market size of MRSA in the world accounts for $9 billion. At present, it is growing at CAGR of 4.8 percent which is estimated to reach $12.40 billion by 2017. The company expects to grab a fair share of this market within 3 years of launch of its novel research product Vancoplus in all major territories of the world.

Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medical Research Center Team. The formulation is the most effective and safe option available in the market to curb the notorious methicillin resistant staphylococcus.

Venus Remedies Share Price

328.30 0.45 (0.14%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.